The DOI matches its Crossref record; 336 of the 336 references it cites were found in a registry or an index.
Ligand-Targeted Drug Delivery
Abstract
Safety and efficacy constitute the major criteria governing regulatory approval of any new drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic agent with a targeting ligand that exhibits little affinity for healthy cells but high affinity for pathologic cells. The probability of regulatory approval can conceivably be further enhanced by exploiting the same targeting ligand, conjugated to an imaging agent, to select patients whose diseased tissues display sufficient targeted receptors for therapeutic efficacy. The focus of this Review is to summarize criteria that must be met during design of ligand-targeted drugs (LTDs) to achieve the required therapeutic potency with minimal toxicity. Because most LTDs are composed of a targeting ligand (e.g., organic molecule, aptamer, protein scaffold, or antibody), spacer, cleavable linker, and therapeutic warhead, criteria for successful design of each component will be described. Moreover, because obstacles to successful drug design can differ among human pathologies, limitations to drug delivery imposed by the unique characteristics of different diseases will be considered. With the explosion of genomic and transcriptomic data providing an ever-expanding selection of disease-specific targets, and with tools for high-throughput chemistry offering an escalating diversity of warheads, opportunities for innovating safe and effective LTDs has never been greater.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Meister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,680
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Coming of age: ten years of next-generation sequencing technologies
Goodwin, S., McPherson, J. D., & McCombie, W. R. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.49 · Cited by 4,352
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Towards a knowledge-based Human Protein Atlas
Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1210-1248 · Cited by 2,440
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Extracellular histones are major mediators of death in sepsis
Xu, J., Zhang, X., Pelayo, R., Monestier, M., Ammollo, C. T., Semeraro, F., Taylor, F. B., Esmon, N. L., Lupu, F., & Esmon, C. T. (2009) · Nature Medicine · doi:10.1038/nm.2053 · Cited by 1,539
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Mucins in cancer: function, prognosis and therapy
Kufe, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2761 · Cited by 1,396
G-protein-coupled receptors and cancer
Dorsam, R. T., & Gutkind, J. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2069 · Cited by 1,388
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Can Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Glutathione Homeostasis and Functions: Potential Targets for Medical Interventions
Lushchak, V. I. (2012) · Journal of Amino Acids · doi:10.1155/2012/736837 · Cited by 1,266
multifunctional enzymes in cancer
Mohamed, M. M., & Sloane, B. F. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1949 · Cited by 1,265
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Self-citationLow, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
Self-citationStoeckli, M., Chaurand, P., Hallahan, D. E., & Caprioli, R. M. (2001) · Nature Medicine · doi:10.1038/86573 · Cited by 1,172
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Ashley, E. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.86 · Cited by 1,116
Endocytic mechanisms for targeted drug delivery☆
BAREFORD, L., & SWAAN, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.008 · Cited by 1,033
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
Properties of the Glomerular Barrier and Mechanisms of Proteinuria
Haraldsson, B., Nyström, J., & Deen, W. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00055.2006 · Cited by 909
Cell-specific targeting of nanoparticles by multivalent attachment of small molecules
Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T., & Josephson, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1159 · Cited by 904
gem-Disubstituent Effect: Theoretical Basis and Synthetic Applications
Jung, M. E., & Piizzi, G. (2005) · Chemical Reviews · doi:10.1021/cr940337h · Cited by 903
MUC1: a multifaceted oncoprotein with a key role in cancer progression
Nath, S., & Mukherjee, P. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.02.007 · Cited by 837
The Hydrodynamic Radii of Macromolecules and Their Effect on Red Blood Cell Aggregation
Armstrong, J. K., Wenby, R. B., Meiselman, H. J., & Fisher, T. C. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.047746 · Cited by 820
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Allostery in Disease and in Drug Discovery
Nussinov, R., & Tsai, C.-J. (2013) · Cell · doi:10.1016/j.cell.2013.03.034 · Cited by 761
scFv Antibody: Principles and Clinical Application
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., & Hamid, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/980250 · Cited by 760
A synthetic IgG-binding domain based on staphylococcal protein A
Nilsson, B., Moks, T., Jansson, B., Abrahmsén, L., Elmblad, A., Holmgren, E., Henrichson, C., Jones, T. A., & Uhlén, M. (1987) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/1.2.107 · Cited by 759
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Subcellular targeting strategies for drug design and delivery
Rajendran, L., Knölker, H.-J., & Simons, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2897 · Cited by 708
Allosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 695
Structural basis for molecular recognition of folic acid by folate receptors
Chen, C., Ke, J., Zhou, X. E., Yi, W., Brunzelle, J. S., Li, J., Yong, E.-L., Xu, H. E., & Melcher, K. (2013) · Nature · doi:10.1038/nature12327 · Cited by 694
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.
Lee, R. J., & Low, P. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41848-5 · Cited by 692
Self-citationPrinciples in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Self-citationAllosteric binding sites on cell-surface receptors: novel targets for drug discovery
Christopoulos, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd746 · Cited by 664
Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 651
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Hsp90 isoforms: functions, expression and clinical importance
Subbarao Sreedhar, A., Kalmár, É., Csermely, P., & Shen, Y.-F. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00229-7 · Cited by 620
Structure-Immunogenicity Relationships of Therapeutic Proteins
Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029275.41323.a6 · Cited by 617
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Binz, H. K., Stumpp, M. T., Forrer, P., Amstutz, P., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00896-9 · Cited by 589
Circulating Histones Are Mediators of Trauma-associated Lung Injury
Abrams, S. T., Zhang, N., Manson, J., Liu, T., Dart, C., Baluwa, F., Wang, S. S., Brohi, K., Kipar, A., Yu, W., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1037oc · Cited by 581
Keefe, A. J., & Jiang, S. (2012) · Nature Chemistry · doi:10.1038/nchem.1213 · Cited by 576
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
Diffusion of Macromolecules in Agarose Gels: Comparison of Linear and Globular Configurations
Pluen, A., Netti, P. A., Jain, R. K., & Berk, D. A. (1999) · Biophysical Journal · doi:10.1016/s0006-3495(99)76911-0 · Cited by 573
Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., & Senter, P. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3212 · Cited by 557
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
ADAM17: a molecular switch to control inflammation and tissue regeneration
Scheller, J., Chalaris, A., Garbers, C., & Rose-John, S. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.005 · Cited by 526
Antibody-drug conjugates—an emerging class of cancer treatment
Diamantis, N., & Banerji, U. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.435 · Cited by 525
Peptide–drug conjugates as effective prodrug strategies for targeted delivery
Wang, Y., Cheetham, A. G., Angacian, G., Su, H., Xie, L., & Cui, H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.015 · Cited by 514
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Extracellular Histones Are Mediators of Death through TLR2 and TLR4 in Mouse Fatal Liver Injury
Xu, J., Zhang, X., Monestier, M., Esmon, N. L., & Esmon, C. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003930 · Cited by 507
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchier, M., & Beger, H. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116001 · Cited by 492
Lang, K., Davis, L., Torres-Kolbus, J., Chou, C., Deiters, A., & Chin, J. W. (2012) · Nature Chemistry · doi:10.1038/nchem.1250 · Cited by 487
Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes
McDevitt, M. R., Chattopadhyay, D., Kappel, B. J., Jaggi, J. S., Schiffman, S. R., Antczak, C., Njardarson, J. T., Brentjens, R., & Scheinberg, D. A. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.039131 · Cited by 452
Szabo, Z., Mena, E., Rowe, S. P., Plyku, D., Nidal, R., Eisenberger, M. A., Antonarakis, E. S., Fan, H., Dannals, R. F., Chen, Y., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0850-8 · Cited by 443
Introducing genetically encoded aldehydes into proteins
Carrico, I. S., Carlson, B. L., & Bertozzi, C. R. (2007) · Nature Chemical Biology · doi:10.1038/nchembio878 · Cited by 438
Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 437
Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells
Huang, Y., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., & Tan, W. (2009) · ChemBioChem · doi:10.1002/cbic.200800805 · Cited by 422
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A. (2000) · Nature Biotechnology · doi:10.1038/81183 · Cited by 419
Release and activity of histone in diseases
Chen, R., Kang, R., Fan, X.-G., & Tang, D. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.337 · Cited by 419
Juweid, M. E., Neumann, R. D., Paik, C. H., Pérez-Bacete, M., Sato, J., van Osdol, W. W., & Weinstein, J. N. (1992) · PubMed · Cited by 406
Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401
Glucose Conjugation for the Specific Targeting and Treatment of Cancer
Calvaresi, E. C., & Hergenrother, P. J. (2013) · Chemical Science · doi:10.1039/c3sc22205e · Cited by 398
Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., Hinrichs, M. J. M., Bezabeh, B. Z., Fleming, R. L., Dimasi, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.008 · Cited by 397
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Use of rodents as models of human diseases
Vandamme, T. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.124301 · Cited by 389
Puig-Kröger, A., Sierra-Filardi, E., Domínguez-Soto, A., Samaniego, R., Corcuera, M. T., Gómez-Aguado, F., Ratnam, M., Sánchez-Mateos, P., & Corbí, A. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2050 · Cited by 389
PEGylation in anti-cancer therapy: An overview
Mishra, P., Nayak, B., & Dey, R. K. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2015.08.011 · Cited by 382
ADAM-17: the enzyme that does it all
Gooz, M. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409231003628015 · Cited by 377
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
Illingworth, J. (1987) · Biochemical Education · doi:10.1016/0307-4412(87)90120-8 · Cited by 365
Addition of the keto functional group to the genetic code of Escherichia coli
Wang, L., Zhang, Z., Brock, A., & Schultz, P. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0234824100 · Cited by 356
High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer
Pick, E., Kluger, Y., Giltnane, J. M., Moeder, C., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4511 · Cited by 356
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Recent advances in the construction of antibody–drug conjugates
Chudasama, V., Maruani, A., & Caddick, S. (2016) · Nature Chemistry · doi:10.1038/nchem.2415 · Cited by 352
van der Velden, V. H. J., te Marvelde, J. G., Hoogeveen, P. G., Bernstein, I. D., Houtsmuller, A. B., Berger, M. S., & van Dongen, J. J. M. (2001) · Blood · doi:10.1182/blood.v97.10.3197 · Cited by 338
Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
Lin, Y. A., Chalker, J. M., Floyd, N., Bernardes, G. J. L., & Davis, B. G. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8026168 · Cited by 330
A general approach to site-specific antibody drug conjugates
Tian, F., Lu, Y., Manibusan, A., Sellers, A., Tran, H., Sun, Y., Phuong, T., Barnett, R., Hehli, B., Song, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321237111 · Cited by 319
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging
Yang, J., Chen, H., Vlahov, I. R., Cheng, J.-X., & Low, P. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601455103 · Cited by 318
Self-citationPlasma membrane glutathione transporters and their roles in cell physiology and pathophysiology
Ballatori, N., Krance, S. M., Marchan, R., & Hammond, C. L. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.004 · Cited by 318
Xia, W., Hilgenbrink, A. R., Matteson, E. L., Lockwood, M. B., Cheng, J.-X., & Low, P. S. (2009) · Blood · doi:10.1182/blood-2008-04-150789 · Cited by 318
Self-citationExtravascular diffusion in normal and neoplastic tissues.
Nugent, L. J., & Jain, R. K. (1984) · PubMed · Cited by 316
Refined three-dimensional solution structure of insect defensin A
Cornet, B., Bonmatin, J.-M., Hetru, C., Hoffmann, J. A., Ptak, M., & Vovelle, F. (1995) · Structure · doi:10.1016/s0969-2126(01)00177-0 · Cited by 316
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Challenges in design and characterization of ligand-targeted drug delivery systems
Muro, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.052 · Cited by 307
Antibody Drug Conjugates for Cancer Therapy
Polakis, P. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.009373 · Cited by 307
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Alternative non-antibody scaffolds for molecular recognition
Skerra, A. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.04.010 · Cited by 300
Wildhagen, K. C. A. A., García de Frutos, P., Reutelingsperger, C. P., Schrijver, R., Aresté, C., Ortega-Gómez, A., Deckers, N. M., Hemker, H. C., Soehnlein, O., & Nicolaes, G. A. F. (2014) · Blood · doi:10.1182/blood-2013-07-514984 · Cited by 298
Maturing antibody–drug conjugate pipeline hits 30
Mullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4009 · Cited by 295
Extracellular histones in tissue injury and inflammation
Allam, R., Kumar, S. V. R., Darisipudi, M. N., & Anders, H.-J. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1148-z · Cited by 294
Mendgen, T., Steuer, C., & Klein, C. D. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201243p · Cited by 290
Iodoacetamide-induced artifact mimics ubiquitination in mass spectrometry
Nielsen, M. L., Vermeulen, M., Bonaldi, T., Cox, J., Moroder, L., & Mann, M. (2008) · Nature Methods · doi:10.1038/nmeth0608-459 · Cited by 286
Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2548 · Cited by 286
Linkers Having a Crucial Role in Antibody–Drug Conjugates
Lu, J., Jiang, F., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040561 · Cited by 285
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Banerjee, S. S., Aher, N., Patil, R., & Khandare, J. (2012) · Journal of Drug Delivery · doi:10.1155/2012/103973 · Cited by 282
Animal models and therapeutic molecular targets of cancer: utility and limitations
Cekanova, M., & Rathore, K. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s49584 · Cited by 274
Drugs for Allosteric Sites on Receptors
Wenthur, C. J., Gentry, P. R., Mathews, T. P., & Lindsley, C. W. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134525 · Cited by 273
Li, N., Lim, R. K. V., Edwardraja, S., & Lin, Q. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2066913 · Cited by 266
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 266
Tugyi, R., Uray, K., Iván, D., Fellinger, E., Perkins, A., & Hudecz, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407677102 · Cited by 264
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Sörensen, J., Velikyan, I., Sandberg, D., Wennborg, A., Feldwisch, J., Tolmachev, V., Orlova, A., Sandström, M., Lubberink, M., Olofsson, H., et al. (2016) · Theranostics · doi:10.7150/thno.13502 · Cited by 264
Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., & Harashima, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.008 · Cited by 254
DARPins: A new generation of protein therapeutics
Stumpp, M. T., Binz, H. K., & Amstutz, P. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.013 · Cited by 254
Targeting C-type lectin receptors with multivalent carbohydrate ligands
Lepenies, B., Lee, J., & Sonkaria, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.007 · Cited by 251
The -Adrenergic Receptors and the Control of Adipose Tissue Metabolism and Thermogenesis
Collins, S. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.309 · Cited by 249
Kummar, S., Chen, H. X., Wright, J., Holbeck, S., Millin, M. D., Tomaszewski, J., Zweibel, J., Collins, J., & Doroshow, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3216 · Cited by 247
Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy-Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2724 · Cited by 245
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic
Vlahov, I. R., & Leamon, C. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc2005522 · Cited by 240
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
Silverman, J., Lu, Q., Bakker, A., To, W., Duguay, A., Alba, B. M., Smith, R., Rivas, A., Li, P., Le, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1166 · Cited by 237
Manjappa, A. S., Chaudhari, K. R., Venkataraju, M. P., Dantuluri, P., Nanda, B., Sidda, C., Sawant, K. K., & Ramachandra Murthy, R. S. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.002 · Cited by 236
Dual pathways of internalization of the cholecystokinin receptor.
Roettger, B. F., Rentsch, R. U., Pinon, D., Holicky, E., Hadac, E., Larkin, J. M., & Miller, L. J. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.6.1029 · Cited by 232
Challenges and opportunities for non-antibody scaffold drugs
Vazquez-Lombardi, R., Phan, T. G., Zimmermann, C., Lowe, D., Jermutus, L., & Christ, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.004 · Cited by 225
Liu, Y., Wang, W., Yang, J., Zhou, C., & Sun, J. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.021 · Cited by 223
Paulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J., & Low, P. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003723 · Cited by 220
Self-citationBioactivation of Self-Immolative Dendritic Prodrugs by Catalytic Antibody 38C2
Shamis, M., Lode, H. N., & Shabat, D. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039052p · Cited by 218
Prodrugs of biologically active phosphate esters
Schultz, C. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00552-7 · Cited by 216
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215
Zhu, G., Niu, G., & Chen, X. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00291 · Cited by 213
A new generation of protein display scaffolds for molecular recognition
Hosse, R. J., Rothe, A., & Power, B. E. (2006) · Protein Science · doi:10.1110/ps.051817606 · Cited by 211
Bosmann, M., Grailer, J. J., Ruemmler, R., Russkamp, N. F., Zetoune, F. S., Sarma, J. V., Standiford, T. J., & Ward, P. A. (2013) · The FASEB Journal · doi:10.1096/fj.13-236380 · Cited by 210
Role of Matrix Metalloproteinases in Intestinal Inflammation
Medina, C., & Radomski, M. W. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103465 · Cited by 201
Sigma-2 receptors as a biomarker of proliferation in solid tumours
Wheeler, K. T., Wang, L.-M., Wallen, C. A., Childers, S. R., Cline, J. M., Keng, P. C., & Mach, R. H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1067 · Cited by 200
Poon, K. A., Flagella, K., Beyer, J., Tibbitts, J., Kaur, S., Saad, O., Yi, J.-H., Girish, S., Dybdal, N., & Reynolds, T. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.09.003 · Cited by 198
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Liu, C., Tadayoni, B. M., Bourret, L. A., Mattocks, K. M., Derr, S. M., Widdison, W. C., Kedersha, N. L., Ariniello, P. D., Goldmacher, V. S., Lambert, J. M., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8618 · Cited by 196
Endocytosis of folate-protein conjugates: ultrastructural localization in kb cells
Turek, J. J., & Low, P. S. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.1.423 · Cited by 196
Self-citationNomura, N., Pastorino, S., Jiang, P., Lambert, G., Crawford, J. R., Gymnopoulos, M., Piccioni, D., Juarez, T., Pingle, S. C., Makale, M., et al. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-26 · Cited by 195
Cathepsin B and its role(s) in cancer progression
Podgorski, I., & Sloane, B. F. (2003) · Biochemical Society Symposia · doi:10.1042/bss0700263 · Cited by 195
Kularatne, S. A., Wang, K., Santhapuram, H.-K. R., & Low, P. S. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900069d · Cited by 191
Self-citationCurrent Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines
Durymanov, M. O., Rosenkranz, A. A., & Sobolev, A. S. (2015) · Theranostics · doi:10.7150/thno.11742 · Cited by 189
Casi, G., & Neri, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00457 · Cited by 189
Sun, C. C., Vaja, V., Babitt, J. L., & Lin, H. Y. (2012) · American Journal of Hematology · doi:10.1002/ajh.23110 · Cited by 185
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012) · Medicinal Research Reviews · doi:10.1002/med.20239 · Cited by 182
Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug Conjugates
Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T., Lenox, J. S., Moser, R. F., Nguyen, M. T., Okeley, N. M., Stone, I. J., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600214 · Cited by 181
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Phillips, A. C., Boghaert, E. R., Vaidya, K. S., Mitten, M. J., Norvell, S., Falls, H. D., DeVries, P. J., Cheng, D., Meulbroek, J. A., Buchanan, F. G., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0901 · Cited by 180
Prodrugs of Phosphonates and Phosphates: Crossing the Membrane Barrier
Wiemer, A. J., & Wiemer, D. F. (2014) · Topics in Current Chemistry · doi:10.1007/128_2014_561 · Cited by 178
Systemic use of tumor necrosis factor alpha as an anticancer agent
Roberts, N. J., Zhou, S., Diaz, L. A., & Holdhoff, M. (2011) · Oncotarget · doi:10.18632/oncotarget.344 · Cited by 177
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy
Zhong, Y.-J., Shao, L., & Li, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1754 · Cited by 173
Antibody-targeted drugs and drug resistance—Challenges and solutions
Shefet-Carasso, L., & Benhar, I. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.001 · Cited by 173
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
Burke, P., Hamilton, J. Z., Jeffrey, S. C., Hunter, J. H., Doronina, S. O., Okeley, N. M., Miyamoto, J. B., Anderson, M. E., Stone, I. J., Ulrich, M. L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0343 · Cited by 172
Kularatne, S. A., Zhou, Z., Yang, J., Post, C. B., & Low, P. S. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000712 · Cited by 171
Self-citationvan Osdol, W. W., Fujimori, K., & Weinstein, J. N. (1991) · PubMed · Cited by 170
Matrix metalloproteinases and periodontal diseases
Sapna, G., Gokul, S., & Bagri‐Manjrekar, K. (2014) · Oral Diseases · doi:10.1111/odi.12159 · Cited by 170
Tissue Microarray: A rapidly evolving diagnostic and research tool
Jawhar, N. M. T. (2009) · Annals of Saudi Medicine · doi:10.4103/0256-4947.51806 · Cited by 170
Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0566 · Cited by 168
Zhao, Z., Meng, H., Wang, N., Donovan, M. J., Fu, T., You, M., Chen, Z., Zhang, X., & Tan, W. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302557 · Cited by 168
Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S. V., Cardillo, T. M., Hansen, H. J., Horak, I. D., Griffiths, G. L., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0204 · Cited by 167
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Dosio, F., Brusa, P., & Cattel, L. (2011) · Toxins · doi:10.3390/toxins3070848 · Cited by 166
Histones trigger sterile inflammation by activating the NLRP 3 inflammasome
Allam, R., Darisipudi, M. N., Tschopp, J., & Anders, H. (2013) · European Journal of Immunology · doi:10.1002/eji.201243224 · Cited by 164
Quantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery
Patel, H., Noolvi, M. N., Sharma, P., Jaiswal, V., Bansal, S., Lohan, S., Suthar, S. K., Abbot, V., Dhiman, S. S., & Bhardwaj, V. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1072-3 · Cited by 164
A Cascade Biodegradable Polymer Based on Alternating Cyclization and Elimination Reactions
DeWit, M. A., & Gillies, E. R. (2009) · Journal of the American Chemical Society · doi:10.1021/ja905343x · Cited by 162
Enzyme-mediated hydrolytic activation of prodrugs
Yang, Y.-H., Aloysius, H., Inoyama, D., Chen, Y., & Hu, L.-Q. (2011) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2011.08.001 · Cited by 162
Behrens, C. R., Ha, E. H., Chinn, L. L., Bowers, S., Probst, G., Fitch-Bruhns, M., Monteon, J., Valdiosera, A., Bermudez, A., Liao-Chan, S., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00432 · Cited by 162
Krishnamurthy, V. M., Estroff, L. A., & Whitesides, G. M. (2006) · Methods and principles in medicinal chemistry · doi:10.1002/3527608761.ch2 · Cited by 160
Matrix metalloproteases: Underutilized targets for drug delivery
Vartak, D. G., & Gemeinhart, R. A. (2007) · Journal of drug targeting · doi:10.1080/10611860600968967 · Cited by 159
van der Heijden, J. W., Oerlemans, R., Dijkmans, B. A. C., Qi, H., van der Laken, C. J., Lems, W. F., Jackman, A. L., Kraan, M. C., Tak, P. P., Ratnam, M., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24219 · Cited by 157
O'Shannessy, D. J., Somers, E. B., Maltzman, J. D., Smale, R., & Fu, Y. (2012) · SpringerPlus · doi:10.1186/2193-1801-1-22 · Cited by 155
A Comprehensive Survey of Small-Molecule Binding Pockets in Proteins
Gao, M., & Skolnick, J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003302 · Cited by 154
Wals, K., & Ovaa, H. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00015 · Cited by 153
Marshall, S. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89242-0 · Cited by 147
von Strandmann, E. P., Hansen, H. P., Reiners, K. S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V. R., Draube, A., Reiser, M., Purr, I., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2177 · Cited by 147
VanBrunt, M. P., Shanebeck, K. D., Caldwell, Z., Johnson, J. E., Thompson, P., Martin, T., Dong, H., Li, G., Xu, H., D’Hooge, F., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00359 · Cited by 144
Stumpp, M. T., Forrer, P., Binz, H. K., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00897-0 · Cited by 144
Ross, S., Spencer, S. D., Holcomb, I. N., Tan, C., Hongo, J.-A., Devaux, B., Rangell, L. K., Keller, G. A., Schow, P. W., Steeves, R. M., et al. (2002) · PubMed · Cited by 144
Cited by
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives
Li, L., Xu, S., Yan, H., Li, X., Yazd, H. S., Li, X., Huang, T., Cui, C., Jiang, J., & Tan, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202003563 · Cited by 432
Versatile Types of Organic/Inorganic Nanohybrids: From Strategic Design to Biomedical Applications
Zhao, N., Yan, L., Zhao, X., Chen, X., Li, A., Zheng, D., Zhou, X., Dai, X., & Xu, F.-J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00401 · Cited by 429
Metadata
- Authors
- Srinivasarao, M., & Low, P. S.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-09-12
- Volume
- 117
- Issue
- 19
- Pages
- 12133-12164
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2754938970
- Cited by
- 605
- References
- 336
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.